Case report
Giant hepatic angiomyolipoma: a case report

Ivan Blokhin, MD, Valeria Chernina, MD, Murat Menglibaev, MD, Dmitry Kalinin, MD, PhD, IFCAP, Wolfgang Schima, PhD and Grigory Karmazanovsky, Msc

1Radiology Department, A.V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russia
2Pathology Department, A.V. Vishnevsky National Medical Research Center of Surgery, Moscow, Russia
3Department of Radiology, Göttlicher Heiland Krankenhaus, Barmherzige Schwestern Krankenhaus and Sankt Josef Krankenhaus, Vinzengruppe, Vienna, Austria

Address correspondence to: Mr Ivan Blokhin
E-mail: blokhin.ioann@gmail.com

ABSTRACT

Hepatic angiomyolipoma (AML) is a rare mesenchymal tumour with an undetermined malignant potential. Clinical symptoms are non-specific. The radiological hallmarks are high vascularization of lesion and presence of macroscopic fat. The proportion of fatty tissue varies significantly and discrepancies between pre-operative imaging and histological findings are observed in more than 50% of cases. Visualization of the draining vein may aid in differentiation between AML and hepatocellular carcinoma with abundant fatty component. Biopsy is indicated in ambiguous cases. Presence of clinical symptoms warrants surgical treatment. We present a clinical case of giant hepatic AML, discuss its typical features and treatment options.

INTRODUCTION

Angiomyolipoma (AML) is a mesenchymal tumour, which is most commonly observed in the kidneys. The second most prevalent localization is the liver. Histologically, AML is composed of smooth muscle cells, adipocytes, thick-walled vessels and, possibly, areas of extramedullary haematopoesis. Mixed, lipomatous (>70% fat), myomatous (<10% fat), and angiomatous subtypes have been described. Positive staining for HMB-45 and Melan-A is pathognomonic for AML. Available clinical reports indicate malignant potential of hepatic AML. We present clinical case of a giant hepatic AML diagnosed via complex radiological examination (ultrasound, CT, MRI) with subsequent intraoperative, histological and immunohistochemical verification.

CASE PRESENTATION

A 41-year-old female with complaints for right-sided upper abdominal pain was admitted to the A.V. Vishnevsky National Medical Research Center of Surgery for diagnostic evaluation and treatment. Ultrasound examination at her local institution had visualized a right liver lobe mass. Biochemical blood assay revealed increased levels of hepatic transaminases.

INVESTIGATIONS

Sonography showed a large heterogeneous hyperechoic lesion with irregular contours and moderate degree of vascularization in the right liver lobe (segments V-VIII) (Figure 1).

CT and MRI (Figures 2 and 3) confirmed the presence of a large soft-tissue hypervascular tumour with a diameter of up to 9.5 cm, irregular contours and peripheral areas of macroscopic fat. Mild diffusion restriction was observed on MRI.

No pseudocapsule was detected.

Treatment and outcome

Due to tumour presentation, high rupture risk and possible malignant nature with differential diagnosis of hepatocellular adenoma and fat-abundant hepatocellular carcinoma, the patient underwent curative surgery. Intraoperatively soft yellow-coloured mass up to 9 cm in diameter was observed. Right liver lobe resection was performed (Figure 4). The postoperative course was unremarkable. Several episodes of self-limiting hyperthermia were noted. The patient was discharged 9 days after the surgery.

Microscopically, the tumour was comprised of mature fatty tissue and large polygonal cells with abundant eosinophilic granular cytoplasm. (Figure 5). Large multinucleated giant and spindle-shaped cells as well as cells with brown pigment were observed. The tumour was abundantly vascularized with focal haemorrhages. No pseudocapsule or
mitoses were detected. Immunohistochemical study revealed the following reactions (Figure 6):

- HMB-45 (clone HMB-45, Cell Marque)—cytoplasmic (+++);
- Melan A (clone A103, DAKO)—cytoplasmic (+/++);
- aSMA (clone 1A4, Cell Marque)—cytoplasmic (+/++);
- S100 (polyclonal, DAKO)—cytoplasmic (+/++);
- Ki-67 <1%.

**DISCUSSION**

In the past, hepatic AML was considered a benign tumour to be managed conservatively. In 2000, Damme et al published first case report of malignant liver AML.5 Months after resection, tumour recurred presenting with multiple liver metastases and portal vein thrombosis. Flemming et al described recurrent hepatic tumours 3 years after operation. The authors also suggested that a proliferation index exceeding 3% and multicentric growth indicate a propensity for recurrence. Deng et al presented a case report of malignant hepatic AML with marked cell atypia, vascular invasion and proliferation index >30%.9

In most cases, hepatic AML is asymptomatic. In a review by Nonomura et al, clinical symptoms included upper abdominal pain, weight loss, malaise, and periodic increase in body temperature.1

The classic radiological criteria of AML are as follows: (1) high vascularization of solid tumour, (2) presence of macroscopic fatty components.10 The percentage of adipose tissue in AML varies from 5 to 90%.11 Therefore, differential diagnosis of AML and other hypervascular liver lesions, in particular HCC with abundant fatty components, is difficult. In a recent retrospective study, all hypervascular AML were misdiagnosed as fat-containing HCC by CT or MRI.12 According to the literature, discrepancies between pre-operative and histological findings are noted in more
than half of cases. In a study by Jeon et al, venous drainage to hepatic vein was noted in 80% of cases with AML and only in 7% of cases with HCC. Thus, visualization of draining vein has a high negative predictive value for HCC with fatty components. In our case, the draining vein was not well visualized, likely due to thick 5 mm slices in the available outpatient CT examination. It was also noted that the majority of tumour vessels in hepatic AML were venous structures connecting with an early draining vein, while most of the pathologic vessels inside HCC were abnormal arteries. Wang et al have also noted that it is difficult to differentiate hepatic AML from fat-containing HCC on MRI as (1) the lesion-to-liver intensity of the two tumour types at the $T_1$- and $T_2$-weighted images was various, and (2) most of the tumours were well-defined, heterogeneous hypervascular enhancing during the arterial phase.

On the other hand, the presence of a pseudocapsule is useful for diagnosing HCC, as this feature is absent in 95–96% cases of AML. The enhancement pattern may be divided into two subtypes: (1) "washout" in lesions with abundant central vessels and "retention" in lesions with small or no vessels. The latter subtype reflects mesenchymal nature of AML.

The treatment options of hepatic AML remain controversial. Some authors, emphasizing the benign nature of the tumour, suggest a wait-and-see approach. Surgical intervention may be entertained if imaging and laboratory studies are equivocal. Ding et al proposed indications for resection as follows: symptomatic patients, tumours greater than 6 cm in size, tumours showing extrahepatic growth and risk of rupture, tumours showing a tendency to grow and equivocal findings at diagnostic imaging and/or biopsy; when a definitive diagnosis cannot be established. The frequency of rupture is still unclear, with only handful of cases reported in the world literature.

Annual follow-up is advised in hepatitis-free patients with high compliance after histological verification if the tumour size is less than 5 cm. If clinical symptoms are present or tumour growth is observed resection is indicated. Radiofrequency ablation may be used if the tumour measures less than 5 cm. Tumour regression is extremely rare.

---

Figure 5. Optical microscopy. (a) The appearance of AML at low magnification. The tumour is sharply circumscribed but non-encapsulated. Note the irregular shape of tumour borders. H&E stain. (b) Magnification 200. The tumour is composed of epithelioid smooth muscle cells with admixture of adipose tissue and thick-walled vessels. This tumour has no pseudocapsule or well-defined border. Note the distribution of tumour cell between hepatocyte plates. H&E stain, (c) The area of clearly different tumour components: adipose tissue; epithelioid smooth muscle cells and thick-walled vessels. There is a small portion of liver tissue (hepatocyte plates and biliary ducts). (d) Magnification 400. A higher magnification demonstrates large, hyperchromatic nuclei with prominent nucleoli. H&E stain. AML, angiomyolipoma.

Figure 6. Immunohistochemistry. (a) Cytoplasmic expression of HMB45 in epithelioid smooth muscle cells. DAB, haematoxylin, magnification 200. (b) Cytoplasmic expression of aSMA in epithelioid smooth muscle cells. DAB, haematoxylin, magnification 200.
LEARNING POINTS

1. Hepatic angiomyolipoma (AML) is a rare mesenchymal tumour with an undetermined malignant potential. Clinical symptoms are nonspecific.

2. The radiological hallmarks are high vascularization of lesion and presence of macroscopic fat. The proportion of fatty tissue varies significantly and discrepancy between preoperative and histological findings is observed in more than 50% of cases.

3. Visualization of the draining and pseudocapsule vein may aid in differentiation between AML and HCC with abundant fatty component. Biopsy is indicated in ambiguous cases.

4. Presence of clinical symptoms warrants surgical treatment.

ACKNOWLEDGMENT

The authors would like to extend their gratitude to Dr. Natalya Karelskaya and Dr. Maria Akhlebinina for their aid in the manuscript preparation.

REFERENCES

1. Nonomura A, Mizukami Y, Kadoya M. Angiomyolipoma of the liver: a collective review. J Gastroenterol 1994; 29: 95–105. doi: https://doi.org/10.1007/BF01229084

2. Yang CY, Ho MC, Jeng YM, Hu RH, Wu YM, Lee PH, MC H, YM W. Management of hepatic angiomyolipoma. J Gastrointest Surg 2007; 11: 452–7. doi: https://doi.org/10.1016/j.jgts.2006.06.003

3. Wolber R. Tumors of the Liver and Intrahepatic Bile Ducts: Atlas of Tumor Pathology, 3rd series, fascicle 31. Am J Surg Pathol 2002; 26: 957–8. doi: https://doi.org/10.1097/00000478-200207000-00023

4. Tsui WM, Colombari R, Portmann BC, Bonetti F, Thung SN, Ferrell LD, et al. Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. Am J Surg Pathol 1999; 23: 34–48.

5. Makhloof HR, Ishak KG, Shekar R, Sesterhenn IA, Young DY, Fanburg-Smith JC. Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study. Arch Pathol Lab Med 2002; 126: 49–55. doi: https://doi.org/10.1043/0003-9985(2002)126<0049:MMAOT>2.0.CO;2

6. Dalle I, Sciot R, de Vos R, Aerts R, van Damme B, Desmet V, Vos D, Damme V, et al. Malignant angiomyolipoma of the liver: a case report with pathological and molecular analysis. Pathol Res Pract 2008; 204: 911–8. doi: https://doi.org/10.1016/j.prp.2008.06.007

7. Flemming P, Lehmann U, Becker T, Klemmpauer J, Kreipe H. Common and epithelioid variants of hepatic angiomyolipoma exhibit clonal growth and share a distinctive immunophenotype. Hepatology 2000; 32: 213–7. doi: https://doi.org/10.1001/hp.2000.9142

8. Croquet V, Pilette C, Aubé C, Rouju R, Oberti F, Cervi C, et al. Late recurrence of a hepatic angiomyolipoma. Eur J Gastroenterol Hepatol 2000, 12: 579–82. doi: https://doi.org/10.1097/00042737-200012050-00018

9. Deng YF, Lin Q, Zhang SH, Ling YM, He JK, Chen XE. Malignant angiomyolipoma in the liver: a report with pathological and molecular analysis. Pathol Res Pract 2008; 204: 911–8. doi: https://doi.org/10.1016/j.prp.2008.06.007

10. Kudo M, Okuno T, Tomita S, Kajiwara T, Shirane H, Usuki N, et al. Hepatic angiomyolipoma pre-operatively diagnosed by imaging. J Gastroenterol Hepatol 1993; 8: 483–8. doi: https://doi.org/10.1111/j.1440-1746.1993.tb01553.x

11. Goodman ZD, Ishak KG. Angiomyolipomas of the liver. Am J Surg Pathol 1984; 8: 745–50. doi: https://doi.org/10.1097/00000478-198410000-00003

12. Ding H, Wei H, Liu H, Chen Y, Xue X, Weng H. The Histopathological Features and CT/MRI Imaging Performances in Hepatic Angiomyolipoma Patients. Am J Surg Pathol 2011; 35: 65–9. doi: https://doi.org/10.1097/00000478-201106000-00007

13. Ahmadi T, Itai Y, Takahashi M, Onaya H, Kobayashi T, Tanaka YO, et al. Angiomyolipoma of the liver: significance of CT and MR dynamic study. Abdom Imaging 1998; 23: 520–6. doi: https://doi.org/10.1007/s002619900391

14. Zhong DR, Ji XL, . Hepatic angiomyolipoma-misdiagnosis as hepatocellular carcinoma: A report of 14 cases. World J Gastroenterol 2000; 6: 608.

15. Jeon TY, Kim SH, Lim HK, Lee WJ. Assessment of triple-phase CT findings for the differentiation of fat-deficient hepatic angiomyolipoma from hepatocellular carcinoma in non-cirrhotic liver. Eur J Radiol 2010; 73: 601–6. doi: https://doi.org/10.1016/j.ejrad.2009.01.010

16. Wang SY, Kuai XP, Meng XX, Jia NY, Dong H. Comparison of MRI features for the differentiation of hepatic angiomyolipoma from fat-containing hepatocellular carcinoma. Abdom Imaging 2014; 39: 323–33. doi: https://doi.org/10.1007/s00261-013-0070-0

17. Ding GH, Liu Y, Wu MC, Yang GS, Yang JM, Cong WM. Diagnosis and treatment of hepatic angiomyolipoma. J Surg Oncol 2011; 103: 807–12. doi: https://doi.org/10.1002/jso.21814

18. Guidi G, Catalano O, Rotondo A. Spontaneous rupture of a hepatic angiomyolipoma: CT findings and literature review. Eur Radiol 1997; 7: 335–7. doi: https://doi.org/10.1007/s0033000500162

19. Huber C, Treutner KH, Steinau G, Schumpeleick V. Ruptured hepatic angiomyolipoma in tuberous sclerosis complex. Langenbecks Arch Chir 1996; 381: 7–9. doi: https://doi.org/10.1007/BF00184248

20. Chang Z, Zhang JM, Ying JQ, Ge YP. Characteristics and treatment strategy of hepatic angiomyolipoma: a series of 94 patients collected from four institutions. J Gastrointestin Liver Dis 2011; 20: 65–9.

21. Wang YJ, Wang YC, Chien CC, Chen CJ, Yang RN, Fang CL. Diagnosis of hepatic angiomyolipoma using CT: report of three cases and review of the literature. Clin Radiol 2009; 64: 329–34. doi: https://doi.org/10.1016/j.crad.2008.09.005